This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges)
Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study
Dependency in basic activities of daily living (bADLs) due to cognitive impairment
Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
History of severe, clinically significant central nervous system trauma
Single group
No Intervention
Other interventionParticipants will have their blood drawn and cognitive score measured by the ISLT.
Concentration of pTau217 in Blood on Day1
Cognitive score in ISLT on Day 1
Click on the lead sponsor to view all of their trials.